KALA BIO EPS KALA
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- −$72.46
- Latest quarter, Q2 FY26
- −$21.32
- Fiscal year 2025
- −$207.13
KALA BIO's earnings per share was −$72.46 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$21.32.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$207.13 | n/a |
| FY2024 | −$551.50 | n/a |
| FY2023 | −$897.00 | n/a |
| FY2022 | −$1491.00 | n/a |
| FY2021 | −$4092.50 | n/a |
| FY2020 | −$2512.50 | n/a |
| FY2019 | −$3450.00 | n/a |
| FY2018 | −$3062.50 | n/a |
| FY2017 | −$23225.00 | n/a |
| FY2016 | −$35100.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$21.32 | n/a | −$72.46 | |
| Q1 FY26 | −$0.14 | n/a | −$136.78 | |
| Q4 FY25 | $2.50 | n/a | −$207.13 | |
| Q3 FY25 | −$53.50 | n/a | −$296.63 | |
| Q2 FY25 | −$85.64 | n/a | −$339.63 | |
| Q1 FY25 | −$70.49 | n/a | −$411.99 | |
| Q4 FY24 | −$87.00 | n/a | −$551.50 | |
| Q3 FY24 | −$96.50 | n/a | −$623.50 | |
| Q2 FY24 | −$158.00 | n/a | −$697.50 | |
| Q1 FY24 | −$210.00 | n/a | −$757.50 | |
| Q4 FY23 | −$159.00 | n/a | −$897.00 | |
| Q3 FY23 | −$170.50 | −118% | −$1136.50 |
Against its peers
Companies in Healthcare nearest KALA BIO's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KALAKALA BIO | −$72.46 | |
| OXBROXBRIDGE RE HOLDINGS | $0.02 | |
| EDUCEducational Development | $0.19 | |
| GTIMGood Times Restaurants | $0.21 | +75% a year |
| MDRRMedalist Diversified | $3.84 | |
| BCGBinah Capital | $0.16 | |
| VIPVulcan Infrastructure & Power | $0.07 | |
| MXCMexco Energy | $0.75 | −5% a year |
| CKXCKX Lands | $1.42 | +647% a year |
| MSGMMotorsport Games | $0.43 | +187% a year |
| ATCHAtlasClear | $0.01 | |
| Peer median | $0.20 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on KALA BIO
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.